Health-Related Quality of Life (HRQoL) of Patients with Tuberculosis: A Review

Sandul Yasobant, Sandul Yasobant, Mahalaqua Nazli Khatib, Zahiruddin Quazi Syed, Abhay M. Gaidhane, Harsh Shah, Priya Bhavsar, Jay Patel, Anish Sinha, Tapasvi Puwar, Somen Saha and Deepak Saxena

1. Department of Public Health Science, Indian Institute of Public Health Gandhinagar (IIPHG), Gandhinagar 382042, India; yasobant@iiphg.org (S.Y.); hdshah@iiphg.org (H.S.); drkirannarkhede@gmail.com (K.N.); priyabhavsar@iiphg.org (P.B.); jpatel@iiphg.org (J.P.); asinha@iiphg.org (A.S.); tpuwar@iiphg.org (T.P); ssaha@iiphg.org (S.S.)

2. School of Epidemiology and Public Health, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha 442004, India; nazli.786@rediffmail.com (M.N.K.); zahirquazi@gmail.com (Z.Q.S.); abhaygaidhane@gmail.com (A.M.G.)

* Correspondence: ddeepak72@iiphg.org

Abstract: Tuberculosis (TB) is a major killer and cause of human suffering worldwide and imposes a substantial reduction in patients’ health-related quality of life (HRQoL). HRQoL indicates the consciousness of patients regarding their physical and mental health. It is, therefore, very relevant in comprehending and measuring the exact impact of the disease state. Therefore, we undertook this review to summarize the available evidence on the impact of TB and its treatment on HRQoL. An in-depth understanding of HRQoL in TB patients can identify the existing management gaps. We included studies that assessed the effect of TB on the QoL both during and after treatment. There are no specific HRQoL assessment tools for utilization among TB patients. HRQoL is markedly impaired in patients with TB. The factors affecting HRQoL differ with active and latent TB, socio-demographics, socio-economic status, presence of co-infections, etc. This review’s findings can help to frame appropriate policies for tackling HRQoL issues in TB patients.

Keywords: HRQoL; QoL; tools; assessment; factors; TB

1. Introduction

Tuberculosis (TB) is the number one infectious killer worldwide, ranking above HIV/AIDS. TB is a significant concern for public health as a key reason for morbidity and mortality, resulting in nearly 4000 deaths a day. Regardless of advancements in identification and management, approximately 10 million people developed TB, and an estimated 1.4 million people died from TB globally in 2019 [1,2]. About one-fourth of the global population has been infected at least once with Mycobacterium tuberculosis in their lifetime [3]. Higher risk is reported in people living with HIV and comorbidities such as malnutrition, diabetes mellitus, substance abuse, etc. TB patients may exhibit a broad range of symptoms, from asymptomatic to symptoms involving single-organ or total manifestations. Fever and cough are the most common reported symptoms [4]. Patients are known to suffer due to the disease symptoms and subsequent decline in patient health-related quality of life (HRQoL) [5,6]. The disease adversely affects all quality of life domains, ranging from physical, economic, and social to psychological distress resulting from stigmatization and discrimination associated with the disease [7]. Quality of life (QoL) is a comprehensive and multifaceted idea that integrates physical, social, mental, economic, and other domains. It defines the satisfaction sensed by an individual and measures the patient’s self-perceived...
health status, functioning, and overall well-being [8]. As QoL emphasizes an “individual’s perception of their position in life in the context of the value systems and culture in which they live and in relation to their expectations, goals, standards, and concerns”, it becomes difficult to assess [9]. Therefore, rather than assessment by healthcare providers, QoL should reflect the inclination and values of the patient. As HRQoL indicates the consciousness of patients regarding their mental and physical health, it is very relevant in comprehending and measuring the exact impact of the disease. However, the existing TB identification and management approaches depend on clinical courses and microbiology, and there is no room to evaluate patients’ physical and psychological health.

With scientific advances in the management strategies for TB, an increasing number of patients can survive the disease. Thus, a change in TB patients’ routine assessment of clinical status and microbiological outcomes is essential. Efficient management of disease relapse, in addition to the appearance of multidrug-resistant tuberculosis (MDR-TB), is linked to the adherence to anti-TB treatment (ATT) and subsequently to HRQoL [10]. The assessment of patient-reported outcomes (PROs) provides evidence about the experience of living with the diseased condition and goes beyond clinical parameters, encompassing physical, mental, and social well-being. Thus, nowadays, PROs are better acknowledged and appreciated in managing diseases and evaluating disease outcomes [11]. Evaluation of HRQoL using PROs permits a complex interpretation of health and aids in measuring the efficacy of treatment on a patient’s health and daily life.

There is a dearth of evidence on assessing HRQoL among TB patients. Further, the effect of a load of TB and ATT on HRQoL in TB patients has been underattended. Systematic reviews by Bauer et al., Chang et al., and Guo et al., [6,7,12] were undertaken several years back. Therefore, we undertook this review to summarize the available evidence on the impact of TB and its treatment on HRQoL. An in-depth understanding of HRQoL in TB patients can identify the existing management gaps. Bridging these gaps will improve and enhance healthcare services and provide provisions for framing health policies. The findings generated in this review can help a range of stakeholders, including patients, caregivers, healthcare providers, practitioners, patient support groups, policymakers, and non-governmental organizations, in designing new approaches and addressing gaps in the care cascade.

2. Methodology

We undertook a systematic search through PubMed and CENTRAL in November 2020 using keywords such as “tuberculosis” and “quality of life” (((tuberculosis [Title/Abstract]) OR (TB [Title/Abstract]) OR (koch*[Title/Abstract])) OR (“tuberculosis” [MeSH Terms]) AND (“quality of life” [Title/Abstract]) OR (QoL [Title/Abstract]) OR (“quality of life” [MeSH Terms])). We additionally searched for key references from bibliographies of the relevant studies. The search was updated in February 2022.

One reviewer independently monitored the retrieved studies against the inclusion criteria, in the beginning, based on title and abstract and then on full texts. Another reviewer also reviewed approximately 20% of these studies to validate the inclusion of studies. Differences were resolved through discussion. One reviewer extracted the data from studies according to the mental, physical, and social health aspects of HRQoL. Data were extracted and tabulated on details about the study design, population, QoL instrument used, QoL domain assessed, and study findings. We included studies that assessed the effect of TB on QoL both during and after treatment irrespective of the study design, geographic location, age, gender, type of TB, or type of treatment. For inclusion, both published and unpublished studies in the English language were considered. We excluded studies that were published in other languages because of resource limitations or if the full-text articles were unavailable to reviewers. We also excluded studies other than TB or TB has been considered as one of the comorbidity along with any other chronic conditions or HR-QoL was not assessed, as shown in Figure 1.
3. Findings

We retrieved 829 initial hits from the literature search in PubMed and CENTRAL. Additional electronic searches, a bibliography of relevant studies, and hand searches yielded 54 studies. Most of the research has been focused on clinical outcomes; only a few studies have scrutinized the impact of tuberculosis on patient quality of life.

3.1. Instruments for Describing and Quantifying QoL in TB

Different questionnaires and scales have been used to assess self-rated HRQoL in TB patients and patients infected with nontuberculous mycobacteria (NTM) [6,7,13,14]. Some questionnaires assess HRQoL holistically, while others assess specific domains, such as physical or emotional domains. HRQoL instruments can be generic or disease-specific. Standardized instruments to assess HRQoL have been used in TB patients [15–17]. Frequently used tools to assess QoL in TB patients include the Short Form 36 (SF-36) [5,11,15–31], the
EQ-5D, [16,24,32–35], and the abbreviated World Health Organization Quality of Life scale (WHOQOL-BREF) [36–42]. TB-specific QoL tools have not been extensively used.

3.2. Factors Associated with HRQoL in TB

Several studies have found that overall well-being, including HRQoL, is strikingly compromised in patients with TB as compared to healthy people across many domains [7,12,15,17,19,20,24,30,33,36,37,40,43–47]. Both general and precise QoL tools showed a broad spectrum of imbalances in scores and outcomes that differed across different countries and different patient groups. The included studies assessed factors associated with HRQoL in TB patients such as socio-demographic factors (age, gender), socio-economic factors (income, education, housing, social security), presence of co-infections (especially HIV) or comorbidities (such as diabetes, anemia), factors associated with ATT (adverse drug reactions), and psycho-social aspects (isolation and stigmatization) [6,7,11,15,21,22,34,36,37,40,44,46,48–55]. Few studies found a larger impact of psycho-social burden than clinical symptoms in TB patients [12,44].

3.2.1. Active and Latent Tuberculosis (LTBI)

Several studies have found that patients with active TB reported poorer HRQoL as compared to patients with LTBI or previously cured TB or untreated individuals or healthy controls [5,6,11,16,21,24,31,40,44,56–60] (Table 1). The psychological domain was more negatively affected than the physical domain among patients with active and latent TB [6]. The HRQoL scores of LTBI patients were normal and similar to those in the general population [59]. The number of people reporting problems was lower in LTBI patients than in patients with active TB [61]. A meta-analysis by Bauer et al. [7] depicted a major improvement in HRQoL during the initial treatment period in patients with active TB.

3.2.2. Socio-Demographic (Age, Gender, and Others) and Socio-Economic (Income, Education, Housing, Social Security) Status

Overall, QoL seems largely independent of age and gender [62,63]. However, some studies reported that advancing age negatively correlated with QoL [21,34,36,48]. Among women, others reported worse QoL [30,36,40]. One study reported that males have unfavorable outcomes in the psychological domain of HRQoL [48]. A study conducted on the Indian subcontinent observed high HRQoL scores in females for the physical and environmental domains, perhaps indicative of improved managing strength in females [40]. Similarly, illiteracy and a low socio-economic state can be linked with larger derangements of HRQoL [31,62]. Higher education had a significant positive impact on the mental domain of HRQoL [64]. The HRQoL differed between developing and developed countries concerning their socio-demographic and economic conditions [65,66]. Tuberculosis had a socio-economic impact on patients and their families. One study found that female TB patients had compromised caregiving abilities, leading to one-fifth of school-going children discontinuing their studies [67].

3.2.3. QoL in Tuberculosis with HIV Co-Infection

In high-burden settings, HIV co-infection is one of the key risk factors for tuberculosis development, escalating the susceptibility to primary infection, reinfecion, and risk of reactivation of TB in patients with latent TB. Thus, we assessed QoL in TB with HIV co-infection. Several studies included patients co-infected with TB and HIV [34,52,54,68–74] (Table 2). Studies [70,71,75] reported lower QoL (physical and mental scores) in people co-infected with HIV and TB compared to TB patients. Few studies [72] found similar scores in HRQoL domains between individuals that received antiretroviral therapy (ART) with ATT and those that received ATT only [69,72].
Table 1. Characteristics of studies that assessed QoL in active and latent tuberculosis (LTBI).

| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|--------------------|--------------|--------------|---------------------|---------------------|----------|
| Shedrawy et al., 2019 (Sweden) [59] | Cross-sectional study | LTBI | 1. EQ-5D-3 L 2. RHS-15 | 1. Physical, 2. Psycho-social 3. Pain | No HRQoL decrements were detected in LTBI patients |
| Bauer et al., 2015 (Canada) [5] | Longitudinal cohort study | 1. Diagnosed and treated for TB disease 2. LTBI 3. Persons screened but not treated for TB disease or LTBI | SF-36 | Eight domain scores and mental and physical component summary | HRQoL decrements detected in TB patients |
| Bauer et al., 2013 [7] | Systematic review and meta-analysis | 1. Active TB 2. LTBI 3. Healthy controls treatment | 1. SF-36 2. GHQ–12 3. HAD 4. MAACL 5. SIP 6. SRI (BDI) 7. EQ 5D 8. WHOQOL-BREF 9. WHOQOL-HIV | 1. Physical 2. Psychological 3. Social 4. Environment | Poorer HRQoL was reported in subjects with active TB than in persons treated for LTBI |
| Kruijshaar et al., 2010 (UK) [24] | Prospective study | Pulmonary TB patients | 1. SF-36 2. EQ-5D 3. SF | 1. Physical 2. Psychological | TB patients had diminished HRQoL scores |
| Guo et al., 2009 [6] | Systematic review and meta-analysis | 1. Active TB 2. LTBI regardless of the treatment status | 1. SF 36 2. EQ-5D 3. EQ-5D 4. VAS 5. QLQ 6. GHQ-12 7. BDQ 8. SRS | 1. Physical 2. Mental 3. Social well-being 4. Functioning | 1. HRQoL decrements in TB patients 2. Among patients in both active and LTBI, mental well-being was more severely disrupted than physical health |
| Marra et al., 2008 [11] | NA | 1. Active TB 2. LTBI | 1. SF-36 2. DI | 1. Physical component summary 2. Mental component summary 3. Depression | HRQoL decrements detected at the completion of therapy in TB patients |
| Unalan et al., 2008 [31] | NA | 1. Active TB 2. Inactive tuberculosis | 1. SF 36 2. BDI | 1. Physical component summary (PCS) 2. Mental component summary 3. Social functionality | QoL decrements detected in active TB patients |
| Guo et al., 2008 (Canada) [21] | NA | 1. Active TB 2. LTBI | 1. SF-36 2. HU12/3 3. VAS | Eight domain scores | For active TB and LTBI, health state utility values did not generate identical utility scores |
### Table 1. Cont.

| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|--------------------|--------------|--------------|---------------------|---------------------|----------|
| Marra et al., 2004 (Canada) [58] | Multi-site study | Active TB patients | Focus groups and individual interviews | 1. Physical functioning and 2. Emotional/mental well-being | QoL decrements detected in active TB patients |
| Dion et al., 2002 (Canada) [57] | NR | 1. Active TB 2. Previous active TB patients | 1. VAS 2. Standard gamble (SG) | 1. Physical component summary (PCS) 2. Mental component summary (MCS) | QoL decrements detected in active TB patients |

BDI: Beck Depression Inventory; BDQ: Brief Disability Questionnaire; EQ 5D: EuroQol; GHQ-12: 12-Item General Health Questionnaire; HUI: Health Utility Index; LTBI: Latent TB Infection; RHS-15: Refugee Health Screening-15; SF-36: Short Form-36; VAS: Visual Analog Scale; WHOQOL: World Health Organization Quality of Life.

### Table 2. Characteristics of studies that assessed QoL in TB with HIV co-infection.

| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|--------------------|--------------|--------------|---------------------|---------------------|----------|
| Opollo et al., 2020 (Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Uganda, Zambia, and Zimbabwe) [74] | Open-label trial | TB patient with advanced HIV infection | Questionnaire | 1. Psychological 2. Economic 3. Socio-cultural 4. Spiritual 5. Physical 6. Psychological 7. Level of independence 8. Social relationships 9. Environmental health 10. Physical health 11. Psychological well-being 12. Social relationship 13. Environmental health 14. Level of independence 15. Spiritual health | HRQoL was found to improve over time, with no difference between arms |
| Hailu et al., 2020 (Ethiopia) [70] | Cross-sectional study | 1. HIV mono-infected 2. TB and HIV co-infected patients | WHOQOL-HIV-BREF | 1. Physical 2. Psychological 3. Level of independence 4. Social relationships 5. Environmental health 6. Spiritual health | Poor HRQoL reported in TB/HIV co-infected patients in all domains compared with HIV mono-infected patients |
| Jha et al., 2019 (India) [71] | Cross-sectional study | 1. HIV-TB co-infected patients 2. HIV patients | 1. WHOQOL-HIV BREF 2. Beck’s Depression Inventory Scale | 1. Physical well-being 2. Functional 3. Global well-being 4. Emotional well-being 5. Cognitive functioning 6. Physical health 7. Psychological well-being 8. Social relationships 9. Environmental health 10. Level of independence 11. Spiritual health | HIV-TB co-infected patients had a poorer QoL than only HIV patients |
| Mthiyane et al., 2016 (South Africa) [72] | Longitudinal study | HIV-TB co-infected patients | FAHI | 1. Physical well-being 2. Functional 3. Global well-being 4. Emotional well-being 5. Cognitive functioning 6. Physical health 7. Psychological well-being 8. Social relationships 9. Environmental health 10. Level of independence 11. Spiritual health | Improvement in QoL consistent with a decrease in adverse events and signs and symptoms of TB |
| Deribew et al., 2013 (Ethiopia) [52] | Prospective study | 1. HIV-infected patients without TB 2. TB/HIV co-infected patients | 1. WHOQOL-HIV-BREF 2. Kessler-10 scale | 1. Physical well-being 2. Functional 3. Global well-being 4. Emotional well-being 5. Cognitive functioning 6. Physical health 7. Psychological well-being 8. Social relationships 9. Environmental health 10. Level of independence 11. Spiritual health | Integrating mental health services into the TB/HIV programs can improve QoL |
| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|--------------------|--------------|--------------|---------------------|---------------------|----------|
| Dowdy et al., 2013 (Brazil) [69] | Cross-sectional study | 1. HIV patients 2. TB patients 3. TB/HIV co-infected patients | 1. Medical Outcomes Study HIV Health Survey (MOS-HIV) 2. Visual Analog Scale (VAS) | 1. Physical health summary 2. Mental health summary 3. Visual Analog Scale | Among patients receiving treatment, those with HIV, active TB, and both conditions were found to have similar QoL. TB and HIV weaken patient’s physical functioning and, thereby, impair QoL. |
| Louw et al., 2012 (South Africa) [54] | Cross-sectional study | 1. TB patients 2. TB re-treatment patients 3. TB-HIV co-infected patients | Social Functioning (SF)-12 Health | 1. Physical health Component 2. Mental health Component | |
| Kittikraisak et al., 2012 (Thailand) [34] | Cross-sectional survey | 1. TB patients 2. HIV-infected TB patients 3. HIV patients | 1. EuroQol (EQ-5D) and 2. EuroQol Visual Analog Scale (EQ-VAS) | 1. Mobility 2. Self-care 3. Usual activities 4. Pain or discomfort 5. Anxiety or depression | Patients with TB and HIV had impaired QoL. |
| Neves et al., 2012 (Brazil) [73] | Cross-sectional study | 1. HIV/TB co-infection patients 2. HIV-positive individuals without TB | WHOQOL-HIV-BREF | 1. Physical 2. Psychological 3. Level of independence 4. Social relations | TB and HIV can alter biopsychosocial factors, which can impair QoL. |
3.2.4. QoL in Tuberculosis with Other Comorbidities

Studies have found that comorbidities such as undernutrition or diabetes mellitus (DM) impact the TB care cascade [76,77]. For other diseased conditions, comorbidities or concomitant treatment is prognostic of lower QoL scores, especially in the physical domain [48]. There is insufficient evidence that the presence of comorbid conditions additionally worsens HRQoL (Table 3).

Table 3. Characteristics of studies that assessed QoL in TB with comorbidities.

| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|--------------------|--------------|--------------|---------------------|---------------------|----------|
| Edwards et al., 2020 (Philippines) [76] | Cross-sectional survey | TB patients with comorbidity with undernutrition, diabetes (DM), and anemia. | WHOQOL-BREF questionnaire | 1. Physical 2. Psychological 3. Social 4. Environmental | Food insecurity and nutritional status denote modifiable risk factors for poor QoL that may be improved through interventions |
| Yeung et al., 2016 [77] | Systematic reviews and meta-analyses | Populations with and without nontuberculous mycobacterial (NTM) disease | 1. SF-36 2. SGRQ/St. George’s Respiratory Questionnaire 3. Visual analog scores (VAS) | 1. Physical 2. Anxiety or depression 3. Pain or discomfort | Pulmonary NTM had worse health outcomes, thus impairing HRQoL |

Nontuberculous mycobacterial (NTM).

3.3. QoL during and after Treatment

The WHO reports that the annual number of TB patients accessing ATT increased from 6 million in 2015 to 7.1 million in 2019 [3]. Several studies have demonstrated that ATT resulted in substantial improvement in HRQoL [4–7,11,15,22,24,36,45,50,51,54,55,78–80] (Table 4). Although HRQoL improves during ATT, most TB patients continue to demonstrate some impairment in HRQoL. While all domains of HRQoL were compromised in TB patients, the maximum impact was observed on the mental domain and least on the physical domain, particularly in the early months of treatment [5]. Integrated TB treatment strategies, such as the TB-tobacco treatment strategy, have been shown to potentially improve overall QoL outcomes among TB patients [50]. HRQoL scores differ with the type of treatment and may be used to identify possible defaulters during ATT [8]. A systematic review by Kastien-Hilka et al. found that, although ATT improved all HRQoL domains, the psycho-social domain remained impaired after treatment [80]. Results of a systematic review [80] suggest that patient-reported HRQoL outcomes may vary after the completion of treatment depending on the HRQoL measures. Studies have indicated that, although HRQoL improved with treatment, it was compromised in TB patients at the initiation and completion of treatment [5,19,24]. The best improvements in HRQoL were observed during the intensive phase of ATT [7]. One study suggested that the HRQoL was low at the completion of ATT [11]. Some studies suggested significant improvements in HRQoL after six months of ATT [29,81]. After the successful completion of ATT, HRQoL scores of TB patients were almost at the same levels as those of the general population [29,82]. Adverse drug reactions (ADR) from ATT may sometimes deteriorate HRQoL more in the mental dimension than the physical dimension [22,28,83,84]. Gastrointestinal disturbances, visual impairment, or peripheral neuropathy associated with ATT may negatively affect HRQoL [44]. Patients with low pre-treatment HRQoL scores demonstrated higher adverse effects than those with normal pre-treatment HRQoL [22].

Studies on HRQoL in MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) patients are very limited. Despite the positive impact of MDR-TB treatment on HRQoL, physical health, mental health, and social functioning are compromised in MDR-TB patients, even after the completion of ATT, as compared to drug-susceptible tuberculosis [18,28,84,85]. Patients with relapse or re-treatment are likely to demonstrate more derangements in QoL [40].
Table 4. Characteristics of studies that assessed QoL in TB during and after treatment.

| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|-------------------|--------------|--------------|---------------------|---------------------|----------|
| Kastien-Hilka et al., 2016 (South Africa) [80] | Systematic review | TB patients | 1. WHOQOL-BREF, 2. SGRQ, 3. SF-36, 4. EQ-5D, 5. BDI, 6. STAI-6, 7. CES-D | 1. Physical, 2. Mental, 3. Social health | Although ATT improved all HRQoL domains, the psycho-social domain remained impaired after treatment |
| Bauer et al., 2015 (Canada) [5] | Longitudinal cohort study | 1. TB, 2. LTBI, 3. Control participants | SF-36 | 1. Physical component summary, 2. Mental component summary | TB patients have lower HRQoL scores; Higher decrements in HRQoL are observed soon after starting ATT but improve after two months of ATT Compromised mental and physical health was observed among TB patients even after the completion of treatment |
| Atif et al., 2014 (Malaysia) [19] | Longitudinal study | New smear-positive PTB patients | SF-36 | 1. Physical, 2. Mental health | |
| Chung and Li, 2013 [79] | Prospective cohort study | TB patients undergoing treatment | WHOQOL-BREF | 1. Physical, 2. Mental, 3. Social, 4. Environmental | TB affects HRQoL despite effective treatment |
| Aggarwal et al., 2013 (India) [36] | Cohort study | Newly diagnosed PTB patients starting treatment (RNTCP) | WHOQOL-BREF | 1. Physical, 2. Psychological, 3. Social relationships, 4. Environment | For patients treated by the RNTCP, HRQoL assessment may be used as an adjunct outcome measure |
| Ralph et al., 2013 (Indonesia) [55] | Clinical trial | 1. Smear-positive TB, 2. Healthy control | SGRQ Indonesian version | 1. Symptoms component, 2. Impact components (social functioning, psychological disturbances resulting from airways disease) | PTB treatment can reduce symptoms, improve functional capacity, and improve QoL |
| Balgude and Sontakke, 2012 [51] | NA | 1. Newly diagnosed pulmonary TB, 2. Healthy control | WHOQOL-BREF | 1. Physical health, 2. Psychological health, 3. Social relationships, 4. Environment | Even after ATT, physical and psychological domains remain lower in TB patients than in controls |
| Awaisu et al., 2012 (Malaysia) [50] | Multi-centered non-randomized controlled study | 1. TB-DOTS plus SCI, 2. TB-DOTS only | 1. EQ-5D, 2. EQ-VAS | 1. Mobility, 2. Self-care, 3. Pain or discomfort, 4. Anxiety or depression | An integrated TB-tobacco treatment strategy can improve HRQoL among smoker TB patients |
| Guo et al., 2010 (Canada) [22] | Longitudinal study | 1. Active TB patients, 2. LTBI patients | SF-36 | 1. PCS, 2. Mental component summary (MCS) | Improvements in the baseline HRQoL of high-risk patients can support the outcome of medical treatment |
| Study ID (Country) | Study Design | Participants | QoL Instrument Used | QoL Domain Assessed | Findings |
|-------------------|--------------|--------------|--------------------|--------------------|----------|
| Kruijshaar et al., 2010 (UK) [24] | NA | TB patients | SF-36 v2 UK versionEQ-5DSTAI-6 CES-D | 1. Physical and general health 2. Vitality and mental health. 3. Anxiety and depression | ATT improved HRQoL but were lower than normal people. |
| Guo et al., 2009 [6] | Systematic review | TB patients | SF-36, GQOLI-74, QLQ, SGRQ, SSRS, BDQ | 1. PCS 2. MCS | TB has impact on patients' QoL even after treatment |
| Marra et al., 2008 [11] | NA | 1. Active TB patients 2. LTBI patients | SF-36 v2BDI | 1. Physical 2. Mental 3. Social 4. Emotional | Active TB patients showed improvements in most HRQoL domains |
| Muniyandi et al., 2007 | NA | (TB) patients one year after treatment completion. | SF-36 | 1. Physical 2. Mental 3. Social well-being 4. Emotional | HRQoL of TB patients after one year of completion of ATT was normal |
| Pasipanodya et al., 2007b (United States) [86] | NA | PTB or latent tuberculosis infection (LTBI) | SGRQ | 1. Symptoms component 2. Impact components (social functioning, psychological disturbances resulting from airways disease) | PTB has a substantial impact on human health, thus affecting QoL. |
| Dion et al., 2004 (Canada) [16] | Cross-sectional study | Pulmonary tuberculosis (PTB) | SF-36v2, SF-12v2 | 1. PCS 2. MCS | Most cured TB patients have compromised HRQoL. |

ATT: anti-tuberculosis treatment; HRQoL: health-related quality of life; PTB: pulmonary tuberculosis; RNTCP: Revised National TB Control Program; MCS: mental component summary; PCS: physical component summary.
4. Discussion

In this review, we collated data from multiple primary studies to furnish fresh insights into HRQoL in TB patients that can be useful to healthcare providers, policymakers, and patient support groups in designing newer approaches and addressing gaps in patient care.

Due to the lack of validated TB-specific instruments for assessing HRQoL, a wide range of tools have been used in TB patients [13]. Studies suggest that overall well-being and HRQoL are clearly impaired across all domains in patients with TB [12,17,36,44,46]. Economic burden due to reduced work capacity, social stigmatization, and psychological issues may deteriorate HRQoL in this population [68]. Several studies have found that subjects with active TB had poorer HRQoL than patients treated for LTBI and untreated individuals [5–7,11,21,24,31,40,44,57–59]. In contrast to active TB, LTBI is usually asymptomatic and does not affect HRQoL. However, diagnosis and treatment for LTBI can be linked with adverse events and mental health challenges. Studies have reported lower HRQoL in co-infected (TB-HIV) individuals as compared to patients with TB [34,54,68,70,71,73,75]. TB co-infection worsens the symptoms of HIV and advances the disease to the next stage, which can further deteriorate the HRQoL [70]. Additionally, studies have found that TB patients are negatively impacted by comorbidities such as undernutrition, diabetes mellitus (DM), anemia, or HIV infection [76,77].

This measure is important in evaluating and measuring the actual effect of disease on patients. Poor baseline HRQoL status may indicate physical and mental health issues, which can lead to a greater risk of undesirable outcomes. Thus, self-reported HRQoL can be considered as an adjunct to disease outcomes and not merely an alternative tool. Lower HRQoL scores have been reported among TB patients at the start of treatment as well as after the completion of ATT [5]. Though all of the HRQoL domains were affected, maximum derangements were observed in mental health dimensions and lowest derangements in physical health dimensions [5]. Although ATT improved HRQoL scores, they remained below normal [5,19,24,87]. HRQoL scores differ with the course of treatment and may even help to recognize possible defaulters during treatment [8]. The possibility of experiencing adverse drug reactions is higher in TB patients with low baseline (pre-treatment) HRQoL scores than those with normal baseline (pre-treatment) HRQoL scores [22]. This implies that HRQoL assessments at baseline (pre-treatment) can help the healthcare provider in recognizing patients likely to develop an ADR to ATT.

TB is known to be a significant cause of mortality and morbidity across the globe. However, the detrimental effects of TB and its treatment on HRQoL are immense and have been unattended. There is scope for considering the assessment of HRQoL at diagnosis as an adjunct outcome measure for evaluation and outcome measure for patients under ATT [11]. The evaluation of the link between HRQoL and adherence to ATT may provide important evidence on treatment efficiency, optimal management of TB patients, and policymaking. These findings call the attention of healthcare providers to tackle issues related to HRQoL in TB patients. The evidence generated in this review emphasizes a possible role in identifying any impairments in HRQoL at diagnosis and providing timely holistic care and patient-centered approaches for improving HRQoL in TB patients.

The authors recommend that concerns related to compromised HRQoL should be dealt with at diagnosis and during treatment in TB patients. Assessment of HRQoL may need to be introduced as an adjunct outcome measure into treatment protocols for TB. Monitoring of HRQoL during follow-up treatment of TB may be necessitated. Patients who may require monitoring can be identified by obtaining HRQoL scores and distinguishing features of defaulters. This can help in tackling the issue of defaulters in TB treatment. Integration of strategies (such as mental health support, socio-cultural reforms, and health education) to improve HRQoL issues is strongly needed to optimize TB care and treatment outcomes.

4.1. Study Limitations

Most studies included in this review were cross-sectional and undertaken in developing countries with the greatest burden of TB. Most studies included participants from
Infect. Dis. Rep. 2022, 14

different socio-economic strata and did not provide socio-demographic details. Explicit descriptions of these details of the participants in the included studies would have made it possible to extract similarities and differences between studies. This would have provided better insights into generalizability and transferability to other settings. The protocol was not registered anywhere.

4.2. Implications for Policy, Practice, and Research

The evidence generated in this review emphasizes the importance of assessing HRQoL in TB patients and encourages decision-making regarding treatment and the possible role of providing timely holistic care approaches in improving HRQoL tailored to patient needs. This review’s findings can help to frame appropriate policies for tackling HRQoL issues in TB patients.

The findings generated in this review point to further research to understand the effect of TB on HRQoL and to develop holistic care approaches to improve the same. Prospective studies can be undertaken to understand the prognostic value of HRQoL further and to study whether this assessment can be used to manage TB patients. Further research on HRQoL in the context of TB is needed to address social and behavioral determinants. Research could also be carried out on vulnerable populations, such as those with TB/HIV co-infection or MDR-TB, young populations, and pregnant women.

5. Conclusions

There are no precise HRQoL assessment tools for TB patients. The authors recommend that a TB-specific QoL assessment tool be developed, standardized, and validated. Poorer HRQoL had been reported in patients with active TB compared to patients with latent TB or previously cured TB, untreated individuals, or healthy controls. Patients co-infected with TB and HIV reported lower QoL as compared to TB patients. There is insufficient evidence as to whether the presence of comorbid conditions additionally worsens HRQoL. Anti-TB treatment can lead to improvement in HRQoL. However, adverse drug reactions from ATT may sometimes provoke the deterioration of HRQoL. This review’s findings can help to frame appropriate policies for tackling HRQoL issues in TB patients.

Author Contributions: Conceptualization: S.Y., M.N.K., Z.Q.S., A.M.G., H.S., K.N., P.B., J.P., A.S., TP, SS. and D.S.; data curation: S.Y., M.N.K., Z.Q.S., A.M.G., H.S., K.N., P.B. and J.P.; formal analysis: S.Y., M.N.K., Z.Q.S., A.M.G., H.S., K.N., P.B. and J.P.; funding acquisition: D.S.; writing—original draft: S.Y., M.N.K., Z.Q.S., A.M.G., H.S., K.N., P.B. and J.P.; writing—review and editing: S.Y., M.N.K., Z.Q.S., A.M.G., H.S., K.N., P.B., J.P., A.S., TP, S.S. and D.S.; Writing—review and editing: S.Y., M.N.K., Z.Q.S., A.M.G., H.S., K.N., P.B., J.P., A.S., TP, S.S. and D.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID). The work described in this article was implemented under the USAID Closing the Gaps in the TB Care Cascade Project, managed by World Health Partners under the terms of Cooperative Agreement Number 72038620CA00012. Staff of the funding agency critically reviewed the draft and offered comments to improve the paper.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All relevant data supporting this study’s findings are within the manuscript.

Acknowledgments: We wish to thank the team of experts from the Indian Institute of Public Health Gandhinagar for providing valuable inputs and feedback to the final draft of the manuscript. We would like to thank the World Health Partners (WHP) for their continuous support in the Closing the Gaps in the TB Care Cascade (CGC) project. We express our sincere thanks to our donor USAID New Delhi, India for funding this study as a part of the larger project, namely, Closing the Gaps in the TB Care Cascade.

Conflicts of Interest: The authors report no conflict of interest in this work.
Disclaimer: The US Agency for International Development administers the US foreign assistance program providing economic and humanitarian assistance in more than 80 countries worldwide. This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government.

References

1. World Health Organization. Ministry of Health of the Russian Federation Moscow Declaration to End TB. First WHO Global Ministerial Conference on Ending TB in the Sustainable Development Era: A Multisectoral Response; Geneva, Switzerland. 2017. Available online: https://www.who.int/tb/features_archive/Moscow_Declaration_to_End_TB_final_ENGLISH.pdf (accessed on 20 March 2021).

2. World Health Organization. *Global Tuberculosis Report 2018*; WHO: Geneva, Switzerland, 2018.

3. World Health Organization. *Global Tuberculosis Report 2020*; WHO: Geneva, Switzerland, 2020. Available online: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf (accessed on 1 April 2021).

4. Banerjee, S.; Bandyopadhyay, K.; Taraphdar, P.; Dasgupta, A. Effect of DOTS on quality of life among tuberculosis patients: A follow-up study in a health district of Kolkata. *J. Family Med. Prim. Care* 2019, 8, 1070–1075. [PubMed]

5. Bauer, M.; Ahmed, S.; Benedetti, A.; Greenaway, C.; Lalli, M.; Leavens, A.; Menzies, D.; Vadeboncoeur, C.; Vissandjee, B.; Wynne, A.; et al. Health-related quality of life and tuberculosis: A longitudinal cohort study. *Health Qual. Life Outcomes* 2015, 13, 65. [CrossRef] [PubMed]

6. Guo, N.; Marra, F.; Marra, C.A. Measuring health-related quality of life in tuberculosis: A systematic review. *Health Qual. Life Outcomes* 2009, 7, 14. [CrossRef] [PubMed]

7. Bauer, M.; Leavens, A.; Schwartzman, K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. *Qual. Life Res.* 2013, 22, 2213–2235. [CrossRef] [PubMed]

8. Brown, J.; Capocci, S.; Smith, C.; Morris, S.; Abubakar, I.; Lipman, M. Health-related quality of life and tuberculosis: A systematic review of qualitative research. *PLoS Med.* 2007, 4, e238. [CrossRef] [PubMed]

9. WHO The World Health Organization Quality of Life assessment (WHOQOL): Position paper from the World Health Organization. *Soc. Sci. Med.* 1995, 41, 1403–1409. [CrossRef]

10. Munro, S.A.; Lewin, S.A.; Smith, H.J.; Engel, M.E.; Fretheim, A.; Volmink, J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. *PLoS Med.* 2007, 4, e238. [CrossRef] [PubMed]

11. Marra, C.A.; Marra, F.; Colley, L.; Moadebi, S.; Elwood, R.K.; Fitzgerald, J.M. Health-related quality of life trajectories among adults with tuberculosis: Differences between latent and active infection. *Chest* 2008, 133, 396–403. [CrossRef]

12. Chang, B.; Wu, A.W.; Hansel, N.N.; Diette, G.B. Quality of life of patients with tuberculosis: A review of the English language literature. *Qual. Life Res.* 2004, 13, 1633–1642. [CrossRef]

13. Brown, J.; Capocci, S.; Smith, C.; Morris, S.; Abubakar, I.; Lipman, M. Health status and quality of life in tuberculosis. *Int. J. Infect. Dis.* 2015, 32, 68–75. [CrossRef]

14. Khan, S.; Tangiisuran, B.; Imtiaz, A.; Zainal, H. Health status and quality of life in tuberculosis: Systematic review of study design, instruments, measuring properties and outcomes. *Health Sci. J.* 2017, 11. Available online: http://www.hsij.gr/medicine/health-status-and-quality-of-life-in-tuberculosis-systematic-review-of-study-design-instruments-measuring-properties-and-outcomes.php?aid=18409 (accessed on 5 April 2021). [CrossRef]

15. Chamla, D. The assessment of patients’ health-related quality of life during tuberculosis treatment in Wuhan, China. *Int. J. Tuberc. Lung Dis.* 2004, 8, 1100–1106. [PubMed]

16. Dion, M.J.; Tousignant, P.; Bourbeau, J.; Menzies, D.; Schwartzman, K. Feasibility and reliability of health-related quality of life assessments among tuberculosis patients. *Qual. Life Res.* 2004, 13, 653–665. [CrossRef] [PubMed]

17. Rajeswari, R.; Muniyandi, M.; Balasubramanian, R.; Narayanan, P.R. Perceptions of tuberculosis patients about their physical, mental and social well-being: A field report from South India. *Soc. Sci. Med.* 2005, 60, 1845–1853. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0277953604004071 (accessed on 5 April 2021). [CrossRef] [PubMed]

18. Ahmad, N.; Javaid, A.; Syed Sulaiman, S.A.; Basit, A.; Afridi, A.K.; Jaber, A.A.S.; Khan, A.H. Effects of multidrug resistant tuberculosis treatment on patients’ health related quality of life: Results from a follow up study. *PloS ONE* 2016, 11, e0159560. [CrossRef]

19. Atif, M.; Sulaiman, S.A.S.; Shafie, A.A.; Asif, M.; Sarfraz, M.K.; Low, H.C.; Babar, Z.-U.-D. Impact of tuberculosis treatment on health-related quality of life of pulmonary tuberculosis patients: A follow-up study. *Health Qual. Life Outcomes* 2014, 12, 19. [CrossRef]

20. dos Santos, A.P.C.; Lazzari, T.K.; Silva, D.R. Health-related quality of life, depression and anxiety in hospitalized patients with Tuberculosis. *Tuberc. Respir. Dis.* 2017, 80, 69–76. [CrossRef]

21. Guo, N.; Marra, C.A.; Marra, F.; Moadebi, S.; Elwood, R.K.; Fitzgerald, J.M. Health State Utilities in Latent and Active Tuberculosis. *Value Health* 2008, 11, 1154–1161. Available online: https://linkinghub.elsevier.com/retrieve/pii/S1098301510605979 (accessed on 10 April 2021). [CrossRef]
22. Guo, N.; Marra, F.; Fitzgerald, J.M.; Elwood, R.K.; Marra, C.A. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. *Eur. Respir. J.* 2010, 36, 206–208. [CrossRef]

23. Jaber, A.A.S.; Khan, A.H.; Syed Sulaiman, S.A.; Ahmad, N.; Anaam, M.S. Evaluation of health-related quality of life among tuberculosis patients in two cities in Vietnam. *PLoS ONE* 2016, 11, e0156258. [CrossRef]

24. Kriujiha, M.E.; Lipman, M.; Essink-Bot, M.-L.; Lozewicz, S.; Creer, D.; Dart, S.; Maguire, H.; Abubakar, I. Health status of UK patients with active tuberculosis. *Int. J. Tuberc. Lung Dis.* 2010, 14, 296–302. [PubMed]

25. Kisaka, S.M.B.; Rutebemberwa, E.; Kasasa, S.; Ocen, F.; Nankya-Mutyoba, J. Does health-related quality of life among adults with pulmonary tuberculosis improve across the treatment period? A hospital-based cross-sectional study in Mbale Region, Eastern Uganda. *BMJ Res. Notes* 2016, 9, 467. [CrossRef] [PubMed]

26. Roba, A.A.; Dasa, T.T.; Weldegebreal, F.; Asfaw, A.; Mitiku, H.; Teklemariam, Z.; Naganuri, M.; Geddegug, B.J.; Mesfin, F.; Befikadu, H.; et al. Tuberculosis patients are physically challenged and socially isolated: A mixed methods case-control study of health related quality of life in Eastern Ethiopia. *PLoS ONE* 2015, 13, e0204697. [CrossRef] [PubMed]

27. Shahdadi, H.; Salarzadeh, M.; Balouchi, A. Quality of life of diabetic patients with smear positive PTB in southeastern Iran: A cross-sectional study in a poor region of Iran. *Indian J. Tuberc.* 2018, 65, 159–163. Available online: https://linkinghub.elsevier.com/retrieve/pii/S0019570717301385 (accessed on 25 May 2021). [CrossRef]

28. Sineke, T.; Evans, D.; Schnippel, K.; van Aswegen, H.; Berhanu, R.; Musakwa, N.; Lönnmark, E.; Long, L.; Rosen, S. The impact of adverse events on health-related quality of life among patients with tuberculosis in Johannesburg, South Africa. *Health Qual. Life Outcomes* 2019, 17, 94. [CrossRef]

29. Ramkumar, S.; Vijayalakshmi, S.; Seetharaman, N.; Pajenivel, R.; Lokeshmaran, A. Health-related quality of life among tuberculosis patients under revised national tuberculosis control programme in rural and urban Puducherry. *Indian J. Tuberc.* 2017, 64, 14–19. [CrossRef]

30. Unalan, D.; Soyuer, F.; Ozturk, A. Comparison of SF-36 and WHOQOL-100 life quality scales in early period tuberculosis subjects. *J. Pak. Med. Assoc.* 2012, 62, 1161–1167.

31. Unalan, D.; Soyuer, F.; Ceyhan, O.; Basturk, M.; Ozturk, A. Is the quality of life different in patients with active and inactive tuberculosis? *Indian J. Tuberc.* 2008, 55, 127–137.

32. Jørstad, M.D.; Assmus, J.; Marijani, M.; Sviland, L.; Mustafa, T. Diagnostic delay in extrapulmonary tuberculosis and impact on patient morbidity: A study from Zanzibar. *PLoS ONE* 2018, 13, e0203593. [CrossRef]

33. Kastien-Hilka, T.; Rosenkranz, B.; Sinanovic, E.; Bennett, B.; Schwenkglenks, M. Health-related quality of life in South African patients with pulmonary tuberculosis. *PLoS ONE* 2017, 12, e0174605. [CrossRef]

34. Kottikraissak, W.; Kingkaew, P.; Teerawattananon, Y.; Yothasamut, J.; Natesuwan, S.; Manosuthi, W.; Chongsuvivatwong, V. Whitehead, S.J. Health related quality of life among patients with tuberculosis and HIV in Thailand. *PLoS ONE* 2012, 7, e29775. [CrossRef] [PubMed]

35. Saleem, S.; Malik, A.A.; Gulam, A.; Ahmed, J.; Hussain, H. Health-related quality of life among pulmonary tuberculosis patients in Pakistan. *Qual. Life Res.* 2018, 27, 3137–3143. [CrossRef] [PubMed]

36. Aggarwal, A.N.; Gupta, D.; Jannuja, A.K.; Jindal, S.K. Assessment of health-related quality of life in patients with pulmonary tuberculosis under programme conditions. *Int. J. Tuberc. Lung Dis.* 2013, 17, 947–953. [CrossRef] [PubMed]

37. Chung, W.-S.; Lan, Y.-L.; Yang, M.-C. Psychometric testing of the short version of the world health organization quality of life assessment for pulmonary tuberculosis patients. *Health Qual. Life Outcomes* 2015, 13, 630. [CrossRef]

38. Dhuria, R.; Yadav, R.; Sharma, M.; Saini, V.; Koushal, V. Quality of life of multi drug resistant tuberculosis patients: A study of north India. *Acta Med. Iran.* 2014, 52, 448–453.

39. Dhuria, M.; Sharma, N.; Singh, N.P.; Jiloha, R.C.; Saha, R.; Ingle, G.K. A study of the impact of tuberculosis on the quality of life and the effect after treatment with DOTS. *Asia Pac. J. Public Health* 2009, 21, 312–320. [CrossRef]

40. Laxmeshwar, C.; Stewart, A.G.; Dalal, A.; Kumar, A.M.V.; Kalaiselvi, S.; Das, M.; Gawde, N.; Thi, S.S.; Isaakidis, P. Beyond “cure” and “treatment success”: Quality of life of patients with multidrug-resistant tuberculosis. *Int. J. Tuberc. Lung Dis.* 2019, 23, 73–81. [CrossRef] [PubMed]

41. Dar, S.A.; Shah, N.N.; Wani, Z.A.; Nazir, D. A prospective study on quality of life in patients with pulmonary tuberculosis at a tertiary care hospital in Kashmir, Northern India. *Indian J. Tuberc.* 2019, 66, 118–122. [CrossRef]

42. Sharma, R.; Yadav, R.; Sharma, M.; Saini, V.; Koushal, V. Quality of life of multi drug resistant tuberculosis patients: A study of north India. *Acta Med. Iran.* 2014, 52, 448–453.

43. Dhuria, M.; Sharma, N.; Ingle, G. Impact of tuberculosis on the quality of life. *Indian J. Community Med.* 2008, 33, 58–59. [CrossRef]

44. Hansel, N.N.; Wu, A.W.; Chang, B.; Diette, G.B. Quality of life in tuberculosis: Patient and provider perspectives. *Qual. Life Res.* 2004, 13, 639–652. [CrossRef] [PubMed]

45. Kastien-Hilka, T.; Rosenkranz, B.; Bennett, B.; Sinanovic, E.; Schwenkglenks, M. How to evaluate health-related quality of life and its association with medication adherence in pulmonary tuberculosis—Designing a prospective observational study in South Africa. *Front. Pharmacol.* 2016, 7, 125. [CrossRef] [PubMed]

46. Masumoto, S.; Yamamoto, T.; Ohkado, A.; Yoshimatsu, S.; Querri, A.G.; Kamiya, Y. Factors associated with health-related quality of life among pulmonary tuberculosis patients in Manila, the Philippines. *Qual. Life Res.* 2014, 23, 1523–1533. [CrossRef] [PubMed]
47. Peddiredy, V. Quality of life, psychological interventions and treatment outcome in tuberculosis patients: The Indian Scenario. 
*Front. Psychol*. 2016, 7, 1664. [CrossRef] [PubMed]

48. Adayeeye, O.O.; Ogunleye, O.O.; Coker, A.; Kuyinu, V.; Bamisile, R.T.; Ekrioko, U.; Onadeko, B. Factors influencing quality of life and predictors of low quality of life scores in patients on treatment for pulmonary tuberculosis: A cross sectional study. *J. Public Health Afr*. 2014, 5, 366. [CrossRef]

49. Aggarwal, A.N. Health-related quality of life: A neglected aspect of pulmonary tuberculosis. *Lung India* 2010, 27, 1–3. [CrossRef]

50. Awaisu, A.; Haniki Nik Mohamed, M.; Noordin, N.M.; Mutalif, A.R.; Aziz, N.A.; Syed Sulaiman, S.A.; Mahayiddin, A.A. Impact of connecting tuberculosis directly observed therapy short-course with smoking cessation on health-related quality of life. *Tob. Induc. Dis.* 2012, 10, 2. [CrossRef]

51. Balgude, A.; Sontakke, S. Study of impact of antitubercular therapy on quality of life. *Indian J. Med. Sci.* 2012, 66, 71–77.

52. Deribew, A.; Deribe, K.; Reda, A.A.; Tesfaye, M.; Hailmichael, Y.; Maja, T.; Colebunders, R. Change in quality of life: A follow up study among patients with HIV infection with and without TB in Ethiopia. *BMJ Public Health* 2013, 13, 408. [CrossRef]

53. Dias, A.A.L.; de Oliveira, D.M.F.; Turato, E.R.; de Figueiredo, R.M. Life experiences of patients who have completed tuberculosis treatment: A qualitative investigation in southeast Brazil. *BMJ Public Health* 2013, 13, 595. [CrossRef]

54. Louw, J.; Pelzer, K.; Naidoo, P.; Matseke, G.; Mchunu, G.; Tutshana, B. Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in three districts in South Africa. *Health Qual. Life Outcomes* 2012, 10, 77. [CrossRef] [PubMed]

55. Ralph, A.P.; Kenangalem, E.; Waramori, G.; Pontororing, G.J.; Tjitra, E.; Maguire, G.P.; Kelly, P.M.; Anstey, N.M. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: Under-recognised phenomena. *PLoS ONE* 2013, 8, e80302. [CrossRef] [PubMed]

56. Dhingra, V.K.; Rajpal, S. Health related quality of life (HRQL) scoring (DR-12 score) in tuberculosis--additional evaluative tool under DOTS. *J. Commun. Dis.* 2005, 37, 261–268. [PubMed]

57. Dion, M.J.; Tousignant, P.; Bourbeau, J.; Menzies, D.; Schwartzman, K. Measurement of health preferences among patients with tuberculosis infection and disease. *Med. Decis. Making* 2002, 22, S102–S114. [CrossRef]

58. Marra, C.A.; Marra, F.; Cox, V.C.; Palepu, A.; Fitzgerald, J.M. Factors influencing quality of life in patients with active tuberculosis. *Health Qual. Life Outcomes* 2004, 2, 58. [CrossRef]

59. Shedrawy, J.; Jansson, L.; Röhl, I.; Kulane, A.; Bruchfeld, J.; Lönnroth, K. Quality of life of patients on treatment for latent tuberculosis infection: A mixed-method study in Stockholm, Sweden. *Health Qual. Life Outcomes* 2019, 17, 158. [CrossRef]

60. Wang, Y.; Li, J.; Lu, F. Measuring and assessing the quality of life of patients with pulmonary tuberculosis. *Xi Za Zhi* 1998, 21, 720–723.

61. Shedrawy, J.; Jansson, L.; Bruchfeld, J.; Lönnroth, K. Health-related quality of life among persons treated for tuberculosis in a European setting. *Int. J. Tuberc. Lung Dis.* 2020, 24, 461–463. [CrossRef]

62. Duyan, V.; Kurt, B.; Aktaş, Z.; Duyan, G.C.; Kulkul, D.O. Relationship between quality of life and characteristics of patients hospitalised with tuberculosis. *Int. J. Tuberc. Lung Dis.* 2005, 9, 1361–1366.

63. Jankowska-Polanska, B.K.; Kamińska, M.; Uchmanowicz, I.; Rycombel, A. Quality of life and health behaviours of patients with tuberculosis—Sex differences. *Pneumonol. Alergot. Pol.* 2015, 83, 256–265. [CrossRef]

64. Louw, J.S.; Mabaso, M.; Pelzer, K. Change in quality of life among pulmonary tuberculosis patients at primary health care settings in South Africa: A prospective cohort study. *PLoS ONE* 2016, 11, e0151892. [CrossRef]

65. Miller, T.L.; McNabb, S.J.N.; Hilsenrath, P.; Pasipanodya, J.; Weis, S.E. Personal and societal health quality lost to tuberculosis. *PLoS ONE* 2009, 4, e5080. [CrossRef] [PubMed]

66. Pasipanodya, J.G.; Miller, T.L.; Vecino, M.; Munguia, G.; Bae, S.; Drewyer, G.; Weis, S.E. Using the St. George respiratory health quality of life profile among HIV infected patients treated for tuberculosis and HIV in a high burden setting. *Qual. Life Res.* 2016, 25, 3067–3076. [CrossRef]

67. de Souza Neves, L.A.; Canini, S.R.M.; Reis, R.K.; Santos, C.B.D.; Gir, E. Aids and tuberculosis: Coinfection from the perspective of the quality of life of patients. *Evista Esc. Enferm. USP* 2012, 46, 704–710.
74. Apollo, V.; Sun, X.; Lando, R.; Miyahara, S.; Torres, T.S.; Hosseinipour, M.C.; Bisson, G.P.; Kumwenda, J.; Gupta, A.; Nyirenda, M.; et al. The effect of TB treatment on health-related quality of life for people with advanced HIV. *Int. J. Tuberc. Lung Dis.* 2020, 24, 910–915. [CrossRef] [PubMed]

75. Babikako, H.M.; Neuhauser, D.; Katamba, A.; Mupere, E. Feasibility, reliability and validity of health-related quality of life questionnaire among adult pulmonary tuberculosis patients in urban Uganda: Cross-sectional study. *Health Qual. Life Outcomes* 2010, 8, 93. [CrossRef]

76. Edwards, T.; White, L.V.; Lee, N.; Castro, M.C.; Saludar, N.R.; Faguer, B.N.; Fuente, N.D.; Mayoga, F.; Ariyoshi, K.; Garfin, A.M.C.G.; et al. Effects of comorbidities on quality of life in Filipino people with tuberculosis. *Int. J. Tuberc. Lung Dis.* 2020, 24, 712–719. [CrossRef]

77. Yeung, M.W.; Khoo, E.; Brode, S.K.; Jamieson, F.B.; Kamiya, H.; Kwong, J.C.; Macdonald, L.; Marras, T.K.; Morimoto, K.; Sander, B. Health-related quality of life, comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: A systematic review. *Respirology* 2016, 21, 1015–1025. [CrossRef] [PubMed]

78. Aggarwal, A.N. Quality of life with tuberculosis. *J. Clin. Tuberc. Other Mycobact. Dis.* 2019, 17, 100121. [CrossRef] [PubMed]

79. Chung, W.-S.; Li, C.-R. Can DOTS improve quality of life among patients with pulmonary tuberculosis? *Int. J. Tuberc. Lung Dis.* 2013, 17, 425–426. [CrossRef]

80. Kastien-Hilka, T.; Abulfathi, A.; Rosenkranz, B.; Bennett, B.; Schwenkglenks, M.; Sinanovic, E. Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis—A systematic review of global literature with focus on South Africa. *Health Qual. Life Outcomes* 2016, 14, 42. [CrossRef]

81. Datta, S.; Gilman, R.H.; Montoya, R.; Quevedo Cruz, L.; Valencia, T.; Huff, D.; Saunders, M.J.; Evans, C.A. Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study. *Eur. Respir. J.* 2020, 56, 1900495. [CrossRef]

82. Salehitali, S.; Noorian, K.; Hafizi, M.; Dehkordi, A.H. Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). *J. Clin. Tuberc. Other Mycobact. Dis.* 2019, 15, 100093. [CrossRef]

83. Valadares, R.M.C.; da Silva Carvalho, W.; de Miranda, S.S. Association of adverse drug reaction to anti-tuberculosis medication with quality of life in patients in a tertiary referral hospital. *Rev. Soc. Bras. Med. Trop.* 2019, 53, e20190207. [CrossRef]

84. Alene, K.A.; Clements, A.C.A.; McBryde, E.S.; Jaramillo, E.; Lönnroth, K.; Shaweno, D.; Gulliver, A.; Viney, K. Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis. *J. Infect.* 2018, 77, 357–367. [CrossRef] [PubMed]

85. Vo, N.X.; Xuan Doan, T.B.; Kha Vo, D.N.; Tran, T.K.; Vo, T.Q. Assessing quality of life for multidrug-resistant and extensively drug-resistant tuberculosis patients. *J. Pak. Med. Assoc.* 2019, 69 (Suppl. 2), S137–S157. [PubMed]

86. Pasipanodya, J.G.; Miller, T.L.; Vecino, M.; Mungua, G.; Garmon, R.; Bae, S.; Drewyer, G.; Weis, S.E. Pulmonary impairment after tuberculosis. *Chest* 2007, 131, 1817–1824. [CrossRef] [PubMed]

87. Atif, M.; Toghrayee, Z.; Sulaiman, S.S.; Shafie, A.A.; Low, H.C.; Babar, Z.U.D. Missing data analysis in longitudinal studies: Findings from a quality of life study in Malaysian Tuberculosis Patients. *Value Health* 2014, 17, A778. [CrossRef]